Dale Bryansmith
Hematology & Oncology · Philadelphia, PANPI 1639284052
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 185 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 9.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,606 and has fallen 98.0% since, to $51 in 2025.
Across 185 payments — averaging $18.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$333
- Bayer$287
- AstraZeneca$257
- Aurobindo Pharma USA, Inc.$197
- Bristol Myers Squibb$196
- Novartis$159
- plus $2K from 34 others
What the payments were for
- Food & beverage$3,33498%
- Education$592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 21 | $333 |
| Bayer | 13 | $287 |
| AstraZeneca(2 entities) | 16 | $257 |
| Aurobindo Pharma USA, Inc. | 3 | $197 |
| Bristol Myers Squibb | 9 | $196 |
| Novartis | 9 | $159 |
| Eisai Inc. | 7 | $138 |
| Sanofi | 8 | $136 |
| E.r. Squibb & Sons, L.L.C. | 9 | $130 |
| Amgen | 6 | $124 |
| Merck | 7 | $113 |
| Tesaro, Inc. | 5 | $107 |
| Astellas Pharma US Inc | 6 | $106 |
| Pfizer | 7 | $106 |
| Lilly USA, LLC | 6 | $84 |
| Seagen Inc. | 5 | $81 |
| Puma Biotechnology, Inc. | 5 | $77 |
| Johnson & Johnson(2 entities) | 3 | $68 |
| Dendreon Pharmaceuticals LLC | 2 | $67 |
| GSK | 3 | $63 |
| Foundation Medicine, Inc. | 4 | $58 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $57 |
| Clovis Oncology, Inc. | 4 | $45 |
| Daiichi Sankyo Inc. | 2 | $45 |
| Gilead(2 entities) | 2 | $31 |
| EMD Serono, Inc. | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| AbbVie | 2 | $28 |
| Tersera Therapeutics LLC | 1 | $26 |
| Taiho Oncology, Inc. | 2 | $26 |
| Incyte Corporation | 2 | $25 |
| Ipsen Biopharmaceuticals, Inc | 1 | $24 |
| Mylan Institutional Inc. | 1 | $23 |
| Verastem, Inc. | 1 | $21 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $18 |
| Novocure Inc. | 1 | $18 |
| Advanced Accelerator Applications | 1 | $16 |
| Fortovia Therapeutics, Inc. | 1 | $14 |
| AMAG Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Folotyn$166
How this compares
$3,393 in reported general payments places this provider in the 60th percentile of 682 hematology & oncology providers in Pennsylvania.
Other hematology & oncology in Philadelphia
- Henry FungPhiladelphia$730K
- Charu AggarwalPhiladelphia$541K
- Corey LangerPhiladelphia$492K
- Ankur ParikhPhiladelphia$329K
- Catherine LaiPhiladelphia$281K
- Stephen SchusterPhiladelphia$218K
- Keith PratzPhiladelphia$173K
- David PorterPhiladelphia$140K
- Adam BinderPhiladelphia$136K
- Marcela MausPhiladelphia$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.